Remission still possible after stopping adalimumab

A real-world pilot study has shown that, while most people coming off adalimumab will have a flare in their rheumatoid arthritis, about 20% do not for at least 28 weeks.

Fifteen of 16 patients, in stable remission on 40mg of adalimumab fortnightly with methotrexate and randomised to continuing treatment, were in remission at 28 weeks compared with five of 15 patients who were taken off the biologic and treated with methotrexate alone.